Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Bio-Techne Corp (TECH) trades at a P/B ratio of 5.4×. Over the past ten years it has ranged from 3.2× (May 2026) to 13.3× (September 2021); the current reading is higher than 46% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2026 5.2× 23.74%
FY2025 4.2× (22.63%)
FY2024 5.5× (16.33%)
FY2023 6.5× (18.36%)
FY2022 8.0× (28.02%)
FY2021 11.1× 52.03%
FY2020 7.3× 7.67%
FY2019 6.8× 31.76%
FY2018 5.1× 11.50%
FY2017 4.6× (3.19%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 5.2× 33.41%
Mar 2026 3.9× (14.04%)
Dec 2025 4.6× 3.59%
Sep 2025 4.4× 4.16%
42 more quarters

Against its own ten years

Low 3.2× High 13.3×
Ten-year median 5.5×
Current reading's percentile 41

P/B ratio against peers

Company P/B ratio
IBRX ImmunityBio, Inc. compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
BMRN BioMarin Pharmaceutical Inc. compare 1.7×
PCVX Vaxcyte, Inc. compare 3.3×
TECH Bio-Techne Corp 5.4×
KRYS Krystal Biotech, Inc. compare 6.9×
CORT Corcept Therapeutics Incorporated compare 16.4×
SMMT Summit Therapeutics PLC compare 18.1×
MDGL Madrigal Pharmaceuticals, Inc. compare 25.0×
Biotechnology industry median 2.1×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on TECH